Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
110 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Dementia - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Dementia - Pipeline Review, H2 2014', provides an overview of the Dementia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Dementia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Dementia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Dementia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Dementia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Dementia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Dementia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Dementia Overview 10 Therapeutics Development 11 Pipeline Products for Dementia - Overview 11 Pipeline Products for Dementia - Comparative Analysis 12 Dementia - Therapeutics under Development by Companies 13 Dementia - Therapeutics under Investigation by Universities/Institutes 15 Dementia - Pipeline Products Glance 17 Clinical Stage Products 17 Early Stage Products 18 Dementia - Products under Development by Companies 19 Dementia - Products under Investigation by Universities/Institutes 21 Dementia - Companies Involved in Therapeutics Development 22 Alector LLC 22 Biotie Therapies Corp. 23 Bristol-Myers Squibb Company 24 Chase Pharmaceuticals Corporation 25 Chronos Therapeutics Limited 26 Echo Pharmaceuticals B.V. 27 FORUM Pharmaceuticals Inc. 28 Hyundai Pharmaceutical Co., Ltd. 29 Ildong Pharmaceutical Co., Ltd. 30 ImStar Therapeutics Inc. 31 Integrative Research Laboratories Sweden AB 32 Intellect Neurosciences, Inc. 33 Intra-Cellular Therapies, Inc. 34 Oryzon Genomics S.A. 35 Pacific Northwest Biotechnology, LLC 36 SK Chemicals Co., Ltd. 37 Stelic Institute & Co. 38 Summit Corporation plc 39 Sylentis S.A. 40 Tautatis Incorporated 41 WhanIn Pharmaceutical Co., Ltd. 42 Dementia - Therapeutics Assessment 43 Assessment by Monotherapy Products 43 Assessment by Target 44 Assessment by Mechanism of Action 46 Assessment by Route of Administration 48 Assessment by Molecule Type 50 Drug Profiles 52 Antibodies for Dementia and Alzheimer's Disease - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Antisense Oligonucleotide to Inhibit microRNA for Neurology - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 choline alfoscerate SR - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 CPC-252 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 dronabinol - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Drugs for Dementia - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Drugs to Agonize c-MET for Dementia - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 FRM-0334 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 GIBH-130 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 gugulipid - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 IPN-007 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 IRL-752 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 ITI-007 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 KR-12 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Monoclonal Antibodies to Inhibit Tau for CNS Disorders - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 NAT - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 NNC-269100 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 OG-635 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Peptide to Inhibit BACE for Cerebropathy and Dementia - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 RDC-5 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 SID-111 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 Small Molecule to Activate LPL for CNS and Metabolic Disorders - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 Small Molecule to Inhibit Glycogene 5 for Dementia - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Small Molecule to Inhibit O-linked N-acetylglucosaminidase for Neurodegenerative Diseases - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 Small Molecules for Ophthalmology and CNS Disorders - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 Small Molecules to Inhibit LSD-1 And MAO-B for Neurodegenerative Diseases - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 Small Molecules to Inhibit TANA for ALS, Dementia and Alzheimer's Disease - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 SYN-120 - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Synthetic Peptides for Neurological Disorders - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 TauC3 Monoclonal Antibody - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 TPI-287 - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 TTT-3002 - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 WIB-1001C - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 Dementia - Recent Pipeline Updates 92 Dementia - Dormant Projects 99 Dementia - Discontinued Products 101 Dementia - Product Development Milestones 102 Featured News & Press Releases 102 Oct 28, 2014: FORUM Pharmaceuticals Presents FRM-0334 Studies at 9th International Conference on Frontotemporal Dementias 102 Sep 19, 2014: Aricept Approved In Japan As Treatment For Dementia With Lewy Bodies 103 Oct 31, 2013: Eisai Submits Application to Expand Indication of Anti-alzheimer's Agent Aricept As Treatment for Dementia with Lewy Bodies in Japan 104 Aug 02, 2012: Namisol phase II study commence in pain in dementia 105 Feb 23, 2011: Intellectual Property High Court of Japan Rules to Maintain Aricept Patent Term Extension in Relation to Severe Alzheimer's Dementia 105 Jul 24, 2010: Eisai Announces U.S. FDA Approval for New Higher Dose Aricept 23mg Tablet for the Treatment of Moderate-to-severe Alzheimer's Disease 105 Nov 24, 2009: FDA Accepts Once Daily 23 mg Aricept Extended Release NDA for Review 106 Sep 25, 2009: Pfizer and Eisai Continue Aricept Collaboration 106 Jul 22, 2009: Eisai Receives Approval for a New Oral Jelly Formulation of Aricept for the Treatment of Alzheimer's Disease in Japan 107 Oct 16, 2006: U.S. Food and Drug Administration Approves ARICEPT for Treatment of Severe Alzheimer's Disease 107 Appendix 109 Methodology 109 Coverage 109 Secondary Research 109 Primary Research 109 Expert Panel Validation 109 Contact Us 110 Disclaimer 110
List of Tables Number of Products under Development for Dementia, H2 2014 11 Number of Products under Development for Dementia - Comparative Analysis, H2 2014 12 Number of Products under Development by Companies, H2 2014 13 Number of Products under Investigation by Universities/Institutes, H2 2014 16 Comparative Analysis by Clinical Stage Development, H2 2014 17 Comparative Analysis by Early Stage Development, H2 2014 18 Products under Development by Companies, H2 2014 19 Products under Development by Companies, H2 2014 (Contd..1) 20 Products under Investigation by Universities/Institutes, H2 2014 21 Dementia - Pipeline by Alector LLC, H2 2014 22 Dementia - Pipeline by Biotie Therapies Corp., H2 2014 23 Dementia - Pipeline by Bristol-Myers Squibb Company, H2 2014 24 Dementia - Pipeline by Chase Pharmaceuticals Corporation, H2 2014 25 Dementia - Pipeline by Chronos Therapeutics Limited, H2 2014 26 Dementia - Pipeline by Echo Pharmaceuticals B.V., H2 2014 27 Dementia - Pipeline by FORUM Pharmaceuticals Inc., H2 2014 28 Dementia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2014 29 Dementia - Pipeline by Ildong Pharmaceutical Co., Ltd., H2 2014 30 Dementia - Pipeline by ImStar Therapeutics Inc., H2 2014 31 Dementia - Pipeline by Integrative Research Laboratories Sweden AB, H2 2014 32 Dementia - Pipeline by Intellect Neurosciences, Inc., H2 2014 33 Dementia - Pipeline by Intra-Cellular Therapies, Inc., H2 2014 34 Dementia - Pipeline by Oryzon Genomics S.A., H2 2014 35 Dementia - Pipeline by Pacific Northwest Biotechnology, LLC, H2 2014 36 Dementia - Pipeline by SK Chemicals Co., Ltd., H2 2014 37 Dementia - Pipeline by Stelic Institute & Co., H2 2014 38 Dementia - Pipeline by Summit Corporation plc, H2 2014 39 Dementia - Pipeline by Sylentis S.A., H2 2014 40 Dementia - Pipeline by Tautatis Incorporated, H2 2014 41 Dementia - Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2014 42 Assessment by Monotherapy Products, H2 2014 43 Number of Products by Stage and Target, H2 2014 45 Number of Products by Stage and Mechanism of Action, H2 2014 47 Number of Products by Stage and Route of Administration, H2 2014 49 Number of Products by Stage and Molecule Type, H2 2014 51 Dementia Therapeutics - Recent Pipeline Updates, H2 2014 92 Dementia - Dormant Projects, H2 2014 99 Dementia - Dormant Projects (Contd..1), H2 2014 100 Dementia - Discontinued Products, H2 2014 101
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
